24% Lower Major Kidney-Disease Event Risk With Semaglutide
A plain-English review of the FLOW trial, where semaglutide reduced major kidney-disease events in adults with type 2 diabetes and CKD in care settings.
The risk of a major kidney-disease event was 24% lower with semaglutide than with placebo (hazard ratio, 0.76).
3,533 adults with type 2 diabetes and chronic kidney disease meeting the trial's eGFR and albuminuria criteria; Median follow-up of 3.4 years. Read the linked peer-reviewed source for the full methodology, findings, and limitations.